PKM2 benefits cancer cells by inhibiting glycolysis and by allowing carbohydrate metabolisms—including uridine diphosphate (UDP)-glucose synthesis, glycerol synthesis, and the hexosamine pathway—to form macromolecular precursors with other adjuvant pathways [24]. This evidence concerns the gene PKM and cancer.